

# 2024 Retinal Pharmaceuticals Market Report: Wet AMD and Other Exudative Diseases

Global Analysis for 2023 to 2029

**\$16.8B**

2023 MARKET  
FORECAST

**296**

COMPREHENSIVE  
PAGES

**40**

COMPETITOR  
PROFILES

**8**

GEOGRAPHIC AND  
ECONOMIC BREAKOUTS

# What's New

AUTHOR  
**Peter Downs**

PUBLISHED  
**September 2024**

The “2024 Retinal Pharmaceuticals Market Report: Wet AMD and Other Exudative Diseases” now focuses on anti-VEGFs and other drugs and drug candidates for exudative retinal diseases and gives updated estimates of the prevalence of diabetes and vision-threatening retinal diseases.

The new report analyzes treatment period trends and IVT injection shares by drug in the United States and Western Europe, reviews the cost per 30 days of wet AMD treatment in the United States, and evaluates more development-stage categories and companies.

## Market Scope


# 2024 Retinal Pharmaceuticals Market Report: Wet AMD & Other Exudative Diseases

The “2024 Retinal Pharmaceuticals Market Report: Wet AMD and Other Exudative Diseases” analyzes the market for anti-VEGFs and other drugs for the treatment of exudative retinal diseases. The report discusses important trends, analyzes key factors for future market success, examines the market’s evolution, and forecasts growth over the next five years. Product demand is forecast in units and dollars, and market shares are analyzed by product category. Additionally, 40 competitors are profiled, with discussion of their products, strategic market position, background, and outlook. Our coverage includes:


- Discussions of retinal diseases and their risk factors.
- Diagnosis and treatment of these diseases.
- A global view of retinal care and retina specialists.
- Retinal pharmaceuticals and biologics in the marketplace.
- Investigational agents in the development pipeline.
- Profiles of companies developing and marketing retinal pharmaceuticals, plus a listing of additional companies with preclinical programs.

The report provides market forecasts for branded ocular anti-VEGFs, cancer drugs used off label, and biosimilars used for the treatment of exudative retinal diseases. The report also includes a separate forecast for sustained drug-delivery devices in retina and also delves into the development pipelines of eight categories of retinal pharmaceuticals.

### Revenue Market Share for Exudative Retinal Disease Pharmaceuticals by Product Type



### Global Prevalence of Exudative Retinal Diseases by Region in 2024



Market Scope designed this report to provide value to members of the ophthalmic industry who participate in the retinal pharmaceuticals market (or are weighing the option of doing so), market analysts, retina specialists, investors, and any other parties interested in the marketplace for these retinal treatments.

## How to Order

Order your “2024 Retinal Pharmaceuticals Market Report: Wet AMD and Other Exudative Diseases” now at [www.market-scope.com](http://www.market-scope.com) or contact us directly via email or phone.



### ENTERPRISE LICENSE

2024 Retinal Pharmaceuticals  
Market Report: Wet AMD and Other  
Exudative Diseases

**\$12,975**

*(Price includes a printable PDF and supplemental Excel file with all the tables and figures in the report)*



### SINGLE-USER LICENSE

2024 Retinal Pharmaceuticals  
Market Report: Wet AMD and Other  
Exudative Diseases

**\$8,650**



Printed Copy

**\$250**



### ONE-YEAR SUBSCRIPTION

Ophthalmic Market  
Perspectives Newsletter

**\$1,650**



Monthly Paper Copies

**\$100**

314.835.0600 | [info@market-scope.com](mailto:info@market-scope.com)

## Our Process

Market Scope’s industry reports are meticulously prepared by a dedicated team of in-house analysts with over 100 years of collective ophthalmic market research experience. Each data point is driven by a combination of sources, including:

- Our proprietary global disease population and demographic models
- Analysis of company-published financial reports
- Focused coverage of ophthalmic scientific research, business news, and other activities
- Attendance and participation in worldwide ophthalmic meetings
- Interviews and relationships with company executives and practicing physicians

